MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 205944 | Name: Aminocamptothecin
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Aminocamptothecin is an inhibitor of Topo I. Aminocamptothecin is an active derivative of camptothecin, which belongs to the general group of chemotherapy drugs called topoisomerase inhibitors.

Chemical Structure

Aminocamptothecin
Aminocamptothecin
CAS#91421-43-1

Theoretical Analysis

MedKoo Cat#: 205944

Name: Aminocamptothecin

CAS#: 91421-43-1

Chemical Formula: C20H17N3O4

Exact Mass: 363.1219

Molecular Weight: 363.37

Elemental Analysis: C, 66.11; H, 4.72; N, 11.56; O, 17.61

Price and Availability

Size Price Availability Quantity
5mg USD 285.00 2 Weeks
10mg USD 500.00 2 Weeks
25mg USD 850.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
9aminocamptothecin; 9aminocamptothecin; 9aminoCPT; 9AC; Aminocamptothecin.
IUPAC/Chemical Name
(S)-10-amino-4-ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
InChi Key
FUXVKZWTXQUGMW-FQEVSTJZSA-N
InChi Code
InChI=1S/C20H17N3O4/c1-2-20(26)13-7-16-17-10(6-11-14(21)4-3-5-15(11)22-17)8-23(16)18(24)12(13)9-27-19(20)25/h3-7,26H,2,8-9,21H2,1H3/t20-/m0/s1
SMILES Code
O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=CC5=C(N)C=CC=C5N=C4C3=C2)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
        

Preparing Stock Solutions

The following data is based on the product molecular weight 363.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
 1: Gao SQ, Sun Y, Kopecková P, Peterson CM, Kopecek J. Antitumor efficacy of colon-specific HPMA copolymer/9-aminocamptothecin conjugates in mice bearing human-colon carcinoma xenografts. Macromol Biosci. 2009 Nov 10;9(11):1135-42. doi: 10.1002/mabi.200900147. PubMed PMID: 19685500. 2: Bartlett NL, Johnson JL, Wagner-Johnston N, Ratain MJ, Peterson BA; Cancer and Leukemia Group B. Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551. Cancer Chemother Pharmacol. 2009 Apr;63(5):793-8. doi: 10.1007/s00280-008-0803-x. Epub 2008 Jul 23. PubMed PMID: 18648813. 3: Gao SQ, Sun Y, Kopecková P, Peterson CM, Kopecek J. Pharmacokinetic modeling of absorption behavior of 9-aminocamptothecin (9-AC) released from colon-specific HPMA copolymer-9-AC conjugate in rats. Pharm Res. 2008 Jan;25(1):218-26. Epub 2007 Oct 11. PubMed PMID: 17929146; PubMed Central PMCID: PMC3136142. 4: Gao SQ, Lu ZR, Kopecková P, Kopecek J. Biodistribution and pharmacokinetics of colon-specific HPMA copolymer--9-aminocamptothecin conjugate in mice. J Control Release. 2007 Feb 12;117(2):179-85. Epub 2006 Oct 27. PubMed PMID: 17150276; PubMed Central PMCID: PMC1839958. 5: Prijovich ZM, Leu YL, Roffler SR. Effect of pH and human serum albumin on the cytotoxicity of a glucuronide prodrug of 9-aminocamptothecin. Cancer Chemother Pharmacol. 2007 Jun;60(1):7-17. Epub 2006 Sep 16. PubMed PMID: 16983566. 6: Torregrossa J, Bubley GJ, Jones GB. Microwave expedited synthesis of 5-aminocamptothecin analogs: Inhibitors of hypoxia inducible factor HIF-1alpha. Bioorg Med Chem Lett. 2006 Dec 1;16(23):6082-5. Epub 2006 Sep 12. PubMed PMID: 16971123. 7: Sewak S, Sorich J, O'Leary J. Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen. Anticancer Drugs. 2006 Jun;17(5):571-9. PubMed PMID: 16702815. 8: Pond CD, Marshall KM, Barrows LR. Identification of a small topoisomerase I-binding peptide that has synergistic antitumor activity with 9-aminocamptothecin. Mol Cancer Ther. 2006 Mar;5(3):739-45. PubMed PMID: 16546989. 9: Zamboni WC, Ramanathan RK, McLeod HL, Mani S, Potter DM, Strychor S, Maruca LJ, King CR, Jung LL, Parise RA, Egorin MJ, Davis TA, Marsh S. Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes. Invest New Drugs. 2006 Sep;24(5):393-401. PubMed PMID: 16505951. 10: Gao SQ, Lu ZR, Petri B, Kopecková P, Kopecek J. Colon-specific 9-aminocamptothecin-HPMA copolymer conjugates containing a 1,6-elimination spacer. J Control Release. 2006 Jan 10;110(2):323-31. Epub 2005 Nov 10. PubMed PMID: 16290118. 11: Zamboni WC, Goel S, Iqbal T, Parise RA, Strychor S, Repinski TV, Egorin MJ, Mani S. Clinical and pharmacokinetic study evaluating the effect of food on the disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in patients with solid tumors. Cancer Chemother Pharmacol. 2006 May;57(5):631-9. Epub 2005 Oct 5. PubMed PMID: 16205924. 12: Zamboni WC, Jung LL, Egorin MJ, Hamburger DR, Joseph E, Jin R, Strychor S, Ramanathan RK, Eiseman JL. Relationship between plasma exposure of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite and antitumor response in mice bearing human colon carcinoma xenografts. Clin Cancer Res. 2005 Jul 1;11(13):4867-74. PubMed PMID: 16000585. 13: Miller DS, Blessing JA, Waggoner S, Schilder J, Sorosky J, Bloss J, Schilder R. Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2005 Jan;96(1):67-71. PubMed PMID: 15589582. 14: Kindler HL, Avadhani A, Wade-Oliver K, Karrison T, Mani S, Vokes EE. 9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium. Invest New Drugs. 2004 Aug;22(3):323-7. PubMed PMID: 15122080. 15: Hochster H, Plimack ER, Runowicz CD, Speyer J, Wallach RC, Sorich J, Mandeli J, Wadler S, Wright J, Muggia FM. Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group. J Clin Oncol. 2004 Jan 1;22(1):120-6. PubMed PMID: 14701774. 16: Zhang J, Burke TG, Latus LJ. Determination of 9-nitrocamptothecin by precolumn derivatization and its metabolite 9-aminocamptothecin in a biological fluid using reversed-phase high-performance liquid chromatography with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Oct 5;795(2):309-18. PubMed PMID: 14522035. 17: Prijovich ZM, Leu YL, Roffler SR. Stability of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in the presence of human serum albumin. Biochem Pharmacol. 2003 Oct 1;66(7):1181-7. PubMed PMID: 14505797. 18: Leguizamo J, Quinn M, Takimoto CH, Liang MD, Ismail AS, Pang J, Dahut W, Grem JL. A phase I study of 9-aminocamptothecin as a colloidal dispersion formulation given as a fortnightly 72-h infusion. Cancer Chemother Pharmacol. 2003 Oct;52(4):333-8. Epub 2003 Jun 18. PubMed PMID: 12819941. 19: Rajendra R, Gounder MK, Saleem A, Schellens JH, Ross DD, Bates SE, Sinko P, Rubin EH. Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin. Cancer Res. 2003 Jun 15;63(12):3228-33. PubMed PMID: 12810652. 20: Xiong HQ, Tran HT, Madden TL, Newman RA, Abbruzzese JL. Phase I and pharmacological study of oral 9-aminocamptothecin colloidal dispersion (NSC 603071) in patients with advanced solid tumors. Clin Cancer Res. 2003 Jun;9(6):2066-71. PubMed PMID: 12796369.